Ionis Pharmaceuticals

We are the leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity.

With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. Therefore, we license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. To date, we have generated more than $1.6 billion from the successful execution of this partnership strategy. 

Furthermore, as the owner or exclusive licensee of more than 1,600 patents worldwide, we lead the RNA-based therapeutic space. We are continually making improvements to our drug discovery platform and our drugs and expanding our antisense technology to include new opportunities. We look forward to remaining the leader in all aspects of antisense technology advancement.
Company Growth (employees)
Type
Public
HQ
Carlsbad, US
Founded
1989
Size (employees)
435 (est)+2%
Ionis Pharmaceuticals was founded in 1989 and is headquartered in Carlsbad, US

Key People at Ionis Pharmaceuticals

Stanley Crooke

Stanley Crooke

CEO
Lynne Parshall

Lynne Parshall

COO / CFO
Elizabeth L. Hougen

Elizabeth L. Hougen

Chief Accounting Officer
C. Frank Bennett

C. Frank Bennett

Senior Vice President of Research
Sarah Boyce

Sarah Boyce

CBO
Steve Hughes

Steve Hughes

Chief Clinical Development Officer
Brett P. Monia

Brett P. Monia

Senior Vice President of Antisense Drug Discovery

Ionis Pharmaceuticals Office Locations

Ionis Pharmaceuticals has office in Carlsbad
Carlsbad, US

Ionis Pharmaceuticals Metrics

Ionis Pharmaceuticals Summary

Market capitalization

$4.9 b

Closing share price

$40.1
Ionis Pharmaceuticals's current market capitalization is $4.9 b.

Ionis Pharmaceuticals Financials

Ionis Pharmaceuticals's revenue is $346.6 m in FY, 2016 which is a 22.2% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$147.3 m$214.2 m$283.7 m$346.6 m

Revenue growth, %

45.4%32.5%22.2%

Net Income

($60.6 m)($39 m)($88.3 m)($86.6 m)

Ionis Pharmaceuticals Market Value History

Ionis Pharmaceuticals Job Categories

Ionis Pharmaceuticals Online Presence

Ionis Pharmaceuticals News

Ionis Pharmaceuticals Company Life

You may also be interested in